- Home
- RIO vs GILD Comparison
RIO vs GILD Comparison
Compare RIO & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIO
- GILD
- Stock Information
- Founded
- RIO 1873
- GILD 1987
- Country
- RIO United Kingdom
- GILD United States
- Employees
- RIO N/A
- GILD N/A
- Industry
- RIO Metal Mining
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RIO Basic Materials
- GILD Health Care
- Exchange
- RIO Nasdaq
- GILD Nasdaq
- Market Cap
- RIO 95.2B
- GILD 113.0B
- IPO Year
- RIO N/A
- GILD 1992
- Fundamental
- Price
- RIO $61.75
- GILD $92.96
- Analyst Decision
- RIO Buy
- GILD Buy
- Analyst Count
- RIO 4
- GILD 26
- Target Price
- RIO $73.00
- GILD $98.17
- AVG Volume (30 Days)
- RIO 3.1M
- GILD 6.5M
- Earning Date
- RIO 02-19-2025
- GILD 02-11-2025
- Dividend Yield
- RIO 7.01%
- GILD 3.32%
- EPS Growth
- RIO 25.31
- GILD N/A
- EPS
- RIO 6.58
- GILD 0.10
- Revenue
- RIO $54,176,000,000.00
- GILD $28,299,000,000.00
- Revenue This Year
- RIO $1.71
- GILD $6.50
- Revenue Next Year
- RIO N/A
- GILD $0.36
- P/E Ratio
- RIO $9.82
- GILD $957.27
- Revenue Growth
- RIO 3.30
- GILD 3.31
- 52 Week Low
- RIO $57.85
- GILD $62.07
- 52 Week High
- RIO $74.24
- GILD $98.90
- Technical
- Relative Strength Index (RSI)
- RIO 59.70
- GILD 56.35
- Support Level
- RIO $58.55
- GILD $90.82
- Resistance Level
- RIO $59.21
- GILD $93.07
- Average True Range (ATR)
- RIO 0.90
- GILD 1.61
- MACD
- RIO 0.46
- GILD 0.08
- Stochastic Oscillator
- RIO 92.63
- GILD 80.85
About RIO Rio Tinto Plc
Rio Tinto is a global diversified miner. Iron ore is the dominant commodity, with significantly lesser contributions from copper, aluminum, diamonds, gold, and industrial minerals. The 1995 merger of RTZ and CRA, via a dual-listed structure, created the present-day company. The two operate as a single business entity, with shareholders in each company having equivalent economic and voting rights. Major assets included the Pilbara iron ore operations, a 30% stake in the Escondida copper mine, 66%-ownership of the Oyu Tolgoi copper mine in Mongolia, the Weipa and Gove bauxite mines in Australia, and six hydro-powered aluminum smelters in Canada.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).